Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47821
Title: | Clinical characteristics, disease activity, functional status, and quality of life results of patients with psoriatic arthritis using biological and conventional synthetic disease-modifying antirheumatic drugs | Authors: | Keskin, Yaşar Nas, Kemal Kılıç, Erkan Sargın, Betül Acer Kasman, Sevtap Alkan, Hakan Şahin, Nilay Cengiz, Gizem Cüzdan, Nihan Albayrak Gezer, İlknur Keskin, Dilek Mülkoğlu, Cevriye Resorlu, Hatice Ataman, Şebnem Bal, Ajda Duruöz, Mehmet Tuncay Küçükakkaş, Okan Yurdakul, Ozan Volkan Alkan Melikoğlu, Meltem Aydın, Yıldıray Figen, Ayhan F. Bodur, Hatice Çalış, Mustafa Çapkın, Erhan Devrimsel, Gül Gök, Kevser Hizmetli, Sami Kamanlı, Ayhan Ecesoy, Hilal Kutluk, Öznur Şen, Nesrin Şendur, Ömer Faruk Tekeoğlu, İbrahim Tolu, Sena Toprak, Murat Tuncer, Tiraje |
Keywords: | Disease-modifying antirheumatic drug Functional status Psoriatic arthritis Quality of life adalimumab biological disease modifying antirheumatic drug certolizumab pegol conventional synthetic disease modifying antirheumatic drug cyclosporine disease modifying antirheumatic drug etanercept golimumab hydroxychloroquine infliximab leflunomide methotrexate salazosulfapyridine secukinumab unclassified drug ustekinumab adult aged Article Bath ankylosing spondylitis disease activity index Bath ankylosing spondylitis functional index body mass clinical feature cohort analysis cross-sectional study DAS28 disease activity female Functional Assessment of Chronic Illness Therapy functional status Health Assessment Questionnaire human major clinical study male monotherapy patient assessment Psoriasis Area and Severity Index psoriatic arthritis quality of life Short Form 36 social interaction swollen joint count tender joint count visual analog scale |
Publisher: | Turkish League Against Rheumatism (TLAR) | Abstract: | Objectives: This study aims to compare the clinical characteristics, disease activity, and quality of life (QoL) of patients with psoriatic arthritis (PsA) who use biological and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in a nationwide cohort throughout Turkey. Patients and methods: A total of 961 patients (346 males, 615 females; mean age: 46.9±12.2 years; range, 18 to 81 years) with PsA according to the classification criteria for PsA were included in the study. The patients’ demographic and clinical characteristics, physical examination results, Disease Activity Score 28, Disease Activity Index for Psoriatic Arthritis and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Psoriasis Area and Severity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, Hospital Anxiety and Depression Scale, Health Assessment Questionnaire, Psoriatic Arthritis Quality of Life (PsAQoL), and Short Form-36 scores were all recorded. Results: Of the patients, 23% underwent biological DMARD (bDMARD) monotherapy, 42% underwent conventional synthetic DMARD (csDMARD) monotherapy, 10% underwent a csDMARD combination therapy, and 10% underwent a combination bDMARD and csDMARD treatment. The Visual Analog Scale (VAS pain), patient global assessment, physician global assessment, and BASDAI scores were found to be lower among patients using combination treatment of csDMARD and bDMARD, while the swollen joint count was found to be lower among patients using bDMARD. The PsAQoL score was found to be the lowest among patients not using any medication and the highest among those using bDMARD. Conclusion: In our study, patients with PsA were successfully treated with both csDMARD and bDMARD monotherapy. When the biological treatments used for PsA were compared with csDMARD, it was found that biological treatments had a positive effect on both disease activity and the QoL. Combinations of csDMARDs and bDMARDs were preferred in cases in which the disease activity was still high or increased. Because of the highest efficacy of the combined treatment, we highly suggest increasing the number of patients on combined treatment. © 2021 Turkish League Against Rheumatism. All rights reserved. | URI: | https://doi.org/10.46497/ArchRheumatol.2021.7874 https://search.trdizin.gov.tr/yayin/detay/465392 https://hdl.handle.net/11499/47821 |
ISSN: | 2148-5046 |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection |
Files in This Item:
CORE Recommender
SCOPUSTM
Citations
7
checked on Dec 21, 2024
Page view(s)
82
checked on Aug 24, 2024
Download(s)
18
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.